Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    cholangiocarcinoma AND stage iiia gallbladder cancer | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
2 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Cholangiocarcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Hilar Cholangiocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Stage II Gallbladder Cancer;   Stage III Childhood Hepatocellular Carcinoma;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Hepatocellular Carcinoma;   Stage IV Distal Bile Duct Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Trametinib;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis
3 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
4 Recruiting Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Conditions: Advanced Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
5 Recruiting Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients With Advanced Gastrointestinal Cancer
Conditions: Adenocarcinoma of Unknown Primary;   Adult Cholangiocarcinoma;   Gallbladder Carcinoma;   Gastric Adenocarcinoma;   Malignant Gastrointestinal Neoplasm;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Stage III Ampulla of Vater Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IV Ampulla of Vater Cancer;   Stage IV Gallbladder Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Drug: Leucovorin Calcium;   Drug: Irinotecan Hydrochloride;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis
6 Unknown  Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Condition: Cancer
Interventions: Drug: oxaliplatin;   Procedure: management of therapy complications

Indicates status has not been verified in more than two years